Skip to main content
. 2013 Apr 30;3:1754. doi: 10.1038/srep01754

Figure 8. Decreased IL-21R and IL-10 in T-bet deficient mice treated in vivo with anti-IL-6R antibody.

Figure 8

(a) Experimental design of anti-IL-6R antibody treatment in vivo.100 μg OVA/Alum was administered to the mice intraperitoneally (i.p.) and 2 mg/ml OVA intranasally (i.n.). Some of the mice also received 75 μg of α-IL-6R antibody or IgG. (b) Irf4 mRNA expression in lung tissue of T-bet(−/−) mice (n = 8–9 mice per group). (c) IL-17A measured by ELISA in the supernatants of total lung cell cultures of T-bet(−/−) mice sensitized and challenged in vivo with OVA and treated in vivo with α-IL-6R antibody. (d) Decreased expression of Il-21R mRNA in lung tissue from T-bet deficient mice treated with anti-IL-6R antibody (n = 3–6 mice per group). (d) Decreased IL-10 in the supernatants of total lung cell cultures of T-bet(−/−) mice sensitized with OVA treated in vivo with α-IL-6R antibody . Students t test was used to calculate statistical significances. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. Results are expressed as mean ± s.e.m.